Chun-Hung Lin1, Chia-Ter Chao2,3, Mei-Yi Wu4,5,6,7, Wei-Cheng Lo6, Tsu-Chen Lin8, Mai-Szu Wu4,5. 1. Department of Orthopedics, Far Eastern Memorial Hospital, New Taipei City, Taiwan. 2. Department of Internal Medicine, National Taiwan University Hospital BeiHu Branch, National Taiwan University College of Medicine, Taipei, Taiwan. b88401084@gmail.com. 3. Graduate Institute of Toxicology, National Taiwan University College of Medicine, No. 1, Section 1 Jen-Ai Rd., Taipei, 10051, Taiwan. b88401084@gmail.com. 4. Department of Nephrology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan. 5. Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 6. Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. 7. Department of Primary Care Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan. 8. School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Abstract
PURPOSE: Mammalian target of rapamycin (mTOR) inhibitors were previously considered a potential therapy for autosomal dominant polycystic kidney disease (ADPKD), but prior studies remained controversial about their efficacy. We performed an updated meta-analysis regarding the therapeutic and adverse effects of mTOR inhibitors in patients with ADPKD. METHODS: We systematically searched Cochrane Library, PubMed, EMBASE, and Medline for randomized controlled trials (RCTs) comparing mTOR inhibitors to placebo in ADPKD patients up to August 2019. We calculated weighted mean differences (WMDs) for total kidney volume (TKV), estimated glomerular filtration rates (eGFRs), and weighted odds ratios (ORs) for treatment-related complications between the treatment and the placebo groups, using the random effects model. RESULTS: We retrieved a total of 9 RCTs enrolling 784 ADPKD patients receiving rapamycin, sirolimus, or everolimus between 2009 and 2016. The WMDs of TKV and eGFR from baseline to the last measurement were - 31.54 mL (95% confidence interval [CI] - 76.79 to 13.71 mL) and 2.81 mL/min/1.73 m2 (95% CI - 1.85 to 7.46 mL/min/1.73 m2), respectively. Patients receiving mTOR inhibitors had a significantly increased risk of any adverse effects (OR 5.92, 95% CI 3.53-9.94), with the most common ones being aphthous stomatitis (OR 15.45, 95% CI 9.68-24.66) and peripheral edema (OR 3.49, 95% CI 1.31-9.27) compared to placebo users. CONCLUSIONS: mTOR inhibitors did not significantly influence renal progression in patients with ADPKD, but were associated with a higher risk of complications. Whether mTOR inhibitors can be an add-on option or second-line agents remain undetermined.
PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors were previously considered a potential therapy for autosomal dominant polycystic kidney disease (ADPKD), but prior studies remained controversial about their efficacy. We performed an updated meta-analysis regarding the therapeutic and adverse effects of mTOR inhibitors in patients with ADPKD. METHODS: We systematically searched Cochrane Library, PubMed, EMBASE, and Medline for randomized controlled trials (RCTs) comparing mTOR inhibitors to placebo in ADPKDpatients up to August 2019. We calculated weighted mean differences (WMDs) for total kidney volume (TKV), estimated glomerular filtration rates (eGFRs), and weighted odds ratios (ORs) for treatment-related complications between the treatment and the placebo groups, using the random effects model. RESULTS: We retrieved a total of 9 RCTs enrolling 784 ADPKDpatients receiving rapamycin, sirolimus, or everolimus between 2009 and 2016. The WMDs of TKV and eGFR from baseline to the last measurement were - 31.54 mL (95% confidence interval [CI] - 76.79 to 13.71 mL) and 2.81 mL/min/1.73 m2 (95% CI - 1.85 to 7.46 mL/min/1.73 m2), respectively. Patients receiving mTOR inhibitors had a significantly increased risk of any adverse effects (OR 5.92, 95% CI 3.53-9.94), with the most common ones being aphthous stomatitis (OR 15.45, 95% CI 9.68-24.66) and peripheral edema (OR 3.49, 95% CI 1.31-9.27) compared to placebo users. CONCLUSIONS:mTOR inhibitors did not significantly influence renal progression in patients with ADPKD, but were associated with a higher risk of complications. Whether mTOR inhibitors can be an add-on option or second-line agents remain undetermined.
Entities:
Keywords:
Autosomal dominant polycystic kidney disease; End-stage renal disease; Estimated glomerular filtration rate; Mammalian target of rapamycin; Total kidney volume
Authors: Zlata Novalic; Annemieke M van der Wal; Wouter N Leonhard; Gudrun Koehl; Martijn H Breuning; Edward K Geissler; Emile de Heer; Dorien J M Peters Journal: J Am Soc Nephrol Date: 2012-02-16 Impact factor: 10.121
Authors: Vicente E Torres; Alessandra Boletta; Arlene Chapman; Vincent Gattone; York Pei; Qi Qian; Darren P Wallace; Thomas Weimbs; Rudolf P Wüthrich Journal: Clin J Am Soc Nephrol Date: 2010-05-24 Impact factor: 8.237
Authors: Melissa Chrispijn; Tom J G Gevers; Jeroen C Hol; Rene Monshouwer; Heleen M Dekker; Joost P H Drenth Journal: J Hepatol Date: 2013-03-14 Impact factor: 25.083
Authors: William E Braun; Jesse D Schold; Brian R Stephany; Rita A Spirko; Brian R Herts Journal: Clin J Am Soc Nephrol Date: 2014-04-10 Impact factor: 8.237
Authors: Qi Qian; Hui Du; Bernard F King; Sumedha Kumar; Patrick G Dean; Fernando G Cosio; Vicente E Torres Journal: J Am Soc Nephrol Date: 2008-01-16 Impact factor: 10.121
Authors: Andreas L Serra; Andreas D Kistler; Diane Poster; Fabienne Krauer; Oliver Senn; Shagun Raina; Ivana Pavik; Katharina Rentsch; Axel Regeniter; Dominik Weishaupt; Rudolf P Wüthrich Journal: Nephrol Dial Transplant Date: 2009-06-13 Impact factor: 5.992
Authors: Davide Bolignano; Suetonia C Palmer; Marinella Ruospo; Carmine Zoccali; Jonathan C Craig; Giovanni F M Strippoli Journal: Cochrane Database Syst Rev Date: 2015-07-14
Authors: Emanuela Senatore; Rosa Iannucci; Francesco Chiuso; Rossella Delle Donne; Laura Rinaldi; Antonio Feliciello Journal: Front Cell Dev Biol Date: 2022-05-11